The American Journal of Human Genetics, ISSN 0002-9297, 2002, Volume 71, Issue 1, pp. 198 - 203
Chronic infantile neurological cutaneous and articular (CINCA) syndrome is a severe chronic inflammatory disease of early onset, characterized by cutaneous...
ENCODING MEVALONATE KINASE | APOPTOSIS | ACTIVATION | DOMAIN | RASH | PROTEIN | GENETICS & HEREDITY | CED-4 | FAMILY | MEMBER | Skin Diseases - genetics | NLR Family, Pyrin Domain-Containing 3 Protein | Humans | Molecular Sequence Data | Infant | Male | Arthritis - genetics | RNA, Messenger - metabolism | Arthritis - congenital | Inflammation - congenital | Blood Proteins - genetics | Base Sequence | Female | Child | Neutrophils - metabolism | Chondrocytes - metabolism | Infant, Newborn | Meningitis - genetics | Amino Acid Sequence | Gene Expression | Meningitis - congenital | RNA, Messenger - genetics | Syndrome | Carrier Proteins - genetics | Pedigree | Inflammation - genetics | Mutation | Chronic Disease | Nervous system diseases | Genetic aspects | Gene mutations | Cutaneous manifestations of general diseases | Cell death | Analysis | Report
ENCODING MEVALONATE KINASE | APOPTOSIS | ACTIVATION | DOMAIN | RASH | PROTEIN | GENETICS & HEREDITY | CED-4 | FAMILY | MEMBER | Skin Diseases - genetics | NLR Family, Pyrin Domain-Containing 3 Protein | Humans | Molecular Sequence Data | Infant | Male | Arthritis - genetics | RNA, Messenger - metabolism | Arthritis - congenital | Inflammation - congenital | Blood Proteins - genetics | Base Sequence | Female | Child | Neutrophils - metabolism | Chondrocytes - metabolism | Infant, Newborn | Meningitis - genetics | Amino Acid Sequence | Gene Expression | Meningitis - congenital | RNA, Messenger - genetics | Syndrome | Carrier Proteins - genetics | Pedigree | Inflammation - genetics | Mutation | Chronic Disease | Nervous system diseases | Genetic aspects | Gene mutations | Cutaneous manifestations of general diseases | Cell death | Analysis | Report
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2011, Volume 64, Issue 5, pp. 827 - 832
Background Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel...
Dermatology | infantile hemangioma | ulceration | propranolol | THERAPY | DYE-LASER | CLINICAL CHARACTERISTICS | INFANCY | DERMATOLOGY | Hemangioma - pathology | Skin Neoplasms - drug therapy | Humans | Propranolol - therapeutic use | Head and Neck Neoplasms - drug therapy | Child, Preschool | Male | Treatment Outcome | Skin Ulcer - etiology | Hemangioma - complications | Skin Ulcer - drug therapy | Propranolol - administration & dosage | Female | Retrospective Studies | Hemangioma - drug therapy | Child | Wound Healing - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Lasers in surgery | Hemangioma | Care and treatment
Dermatology | infantile hemangioma | ulceration | propranolol | THERAPY | DYE-LASER | CLINICAL CHARACTERISTICS | INFANCY | DERMATOLOGY | Hemangioma - pathology | Skin Neoplasms - drug therapy | Humans | Propranolol - therapeutic use | Head and Neck Neoplasms - drug therapy | Child, Preschool | Male | Treatment Outcome | Skin Ulcer - etiology | Hemangioma - complications | Skin Ulcer - drug therapy | Propranolol - administration & dosage | Female | Retrospective Studies | Hemangioma - drug therapy | Child | Wound Healing - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Lasers in surgery | Hemangioma | Care and treatment
Journal Article
European Urology, ISSN 0302-2838, 2002, Volume 41, Issue 5, pp. 497 - 507
Objective: While the lipido-sterolic extract of Serenoa repens (LSESr)-Permixon®-has been shown to have an equivalent efficacy to finasteride in patients with...
α-blockers | BPH, I-PSS | Serenoa repens | Tamsulosin | Permixon | Phytotherapy | MULTICENTER | LIPIDOSTEROLIC EXTRACT | METAANALYSIS | EFFICACY | phytotherapy | alpha-blockers | FINASTERIDE | SERENOA-REPENS PERMIXON(R) | TRIAL | I-PSS | URINARY-TRACT SYMPTOMS | TOLERABILITY | OBSTRUCTION | UROLOGY & NEPHROLOGY | BPH | tamsulosin | Severity of Illness Index | Prostatic Hyperplasia - pathology | Double-Blind Method | Humans | Middle Aged | Adrenergic alpha-Antagonists - therapeutic use | Urodynamics - drug effects | Male | Treatment Outcome | Prostate-Specific Antigen - blood | Serenoa | Adrenergic alpha-Antagonists - adverse effects | Sulfonamides - therapeutic use | Aged, 80 and over | Androgen Antagonists - therapeutic use | Prostate-Specific Antigen - drug effects | Sulfonamides - adverse effects | Aged | Androgen Antagonists - adverse effects | Plant Extracts - therapeutic use | Prostatic Hyperplasia - drug therapy | Plant Extracts - adverse effects
α-blockers | BPH, I-PSS | Serenoa repens | Tamsulosin | Permixon | Phytotherapy | MULTICENTER | LIPIDOSTEROLIC EXTRACT | METAANALYSIS | EFFICACY | phytotherapy | alpha-blockers | FINASTERIDE | SERENOA-REPENS PERMIXON(R) | TRIAL | I-PSS | URINARY-TRACT SYMPTOMS | TOLERABILITY | OBSTRUCTION | UROLOGY & NEPHROLOGY | BPH | tamsulosin | Severity of Illness Index | Prostatic Hyperplasia - pathology | Double-Blind Method | Humans | Middle Aged | Adrenergic alpha-Antagonists - therapeutic use | Urodynamics - drug effects | Male | Treatment Outcome | Prostate-Specific Antigen - blood | Serenoa | Adrenergic alpha-Antagonists - adverse effects | Sulfonamides - therapeutic use | Aged, 80 and over | Androgen Antagonists - therapeutic use | Prostate-Specific Antigen - drug effects | Sulfonamides - adverse effects | Aged | Androgen Antagonists - adverse effects | Plant Extracts - therapeutic use | Prostatic Hyperplasia - drug therapy | Plant Extracts - adverse effects
Journal Article
Psychotherapy and Psychosomatics, ISSN 0033-3190, 06/2019, Volume 88, Issue 3, pp. 171 - 176
Background: MRI studies in patients with bipolar disorder have suggested that lithium is associated with grey matter increases that may underlie its...
Clinical Note | Lithium therapy | GRAY | WHITE-MATTER | PSYCHIATRY | NEURITE ORIENTATION DISPERSION | ADULTS | Bipolar disorder | PSYCHOLOGY | Neurite density | BRAIN STRUCTURE | Grey matter increase | INCREASE | SCALE | Life Sciences | Human health and pathology | Psychiatrics and mental health
Clinical Note | Lithium therapy | GRAY | WHITE-MATTER | PSYCHIATRY | NEURITE ORIENTATION DISPERSION | ADULTS | Bipolar disorder | PSYCHOLOGY | Neurite density | BRAIN STRUCTURE | Grey matter increase | INCREASE | SCALE | Life Sciences | Human health and pathology | Psychiatrics and mental health
Journal Article
Pediatric Allergy and Immunology, ISSN 0905-6157, 1998, Volume 9, Issue 3, pp. 116 - 124
There is a common progression known as the allergic march from atopic dermatitis to allergic asthma. Cetirizine has several antiallergic properties that...
Prevention | IgE | Grass pollen | Infant | House dust mite | Cetirizine | Child | Dermatitis | Asthma | Atopy | RECRUITMENT | house dust mite | atopy | asthma | BRONCHIAL EOSINOPHIL | IMMUNOLOGY | infant | grass pollen | CHILDREN | ATOPIC-DERMATITIS | CHALLENGE | cetirizine | dermatitis | ALLERGY | PEDIATRICS | KETOTIFEN | prevention | EXPOSURE | child
Prevention | IgE | Grass pollen | Infant | House dust mite | Cetirizine | Child | Dermatitis | Asthma | Atopy | RECRUITMENT | house dust mite | atopy | asthma | BRONCHIAL EOSINOPHIL | IMMUNOLOGY | infant | grass pollen | CHILDREN | ATOPIC-DERMATITIS | CHALLENGE | cetirizine | dermatitis | ALLERGY | PEDIATRICS | KETOTIFEN | prevention | EXPOSURE | child
Journal Article
The American Journal of Human Genetics, ISSN 0002-9297, 1998, Volume 62, Issue 6, pp. 1416 - 1424
There is genetic predisposition associated with ⩾10% of all cancer of the prostate (CaP). By means of a genomewide search on a selection of 47 French and...
Chromosome 1q | Cancer, prostate | Linkage | Early onset | Prostate cancer | FAMILY HISTORY | BREAST-CANCER | MULTILOCUS LINKAGE ANALYSIS | FREQUENCIES | LOD SCORE | GENETICS & HEREDITY | RISK | INHERITANCE | CARCINOMA | Genetic Predisposition to Disease | Chromosomes, Human, Pair 1 | Prostatic Neoplasms - genetics | Humans | Age of Onset | Genotype | Male | Chromosome Mapping | Genetic Heterogeneity | Lod Score | Microsatellite Repeats | Genetic Linkage | Chromosome mapping | Usage | Genetic aspects | Genetic disorders | Research
Chromosome 1q | Cancer, prostate | Linkage | Early onset | Prostate cancer | FAMILY HISTORY | BREAST-CANCER | MULTILOCUS LINKAGE ANALYSIS | FREQUENCIES | LOD SCORE | GENETICS & HEREDITY | RISK | INHERITANCE | CARCINOMA | Genetic Predisposition to Disease | Chromosomes, Human, Pair 1 | Prostatic Neoplasms - genetics | Humans | Age of Onset | Genotype | Male | Chromosome Mapping | Genetic Heterogeneity | Lod Score | Microsatellite Repeats | Genetic Linkage | Chromosome mapping | Usage | Genetic aspects | Genetic disorders | Research
Journal Article
UROLOGY, ISSN 0090-4295, 03/1994, Volume 43, Issue 3, pp. 284 - 294
Objective. To assess the long-term safety and efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia in patients treated with...
RESECTION | MEN | UROLOGY & NEPHROLOGY | SYMPTOMS | AGE
RESECTION | MEN | UROLOGY & NEPHROLOGY | SYMPTOMS | AGE
Journal Article
The Journal of Urology, ISSN 0022-5347, 1995, Volume 153, Issue 3, pp. 669 - 673
The impact of symptoms of prostatism on level of bother and quality of life of French men was assessed nationwide, in a representative community sample of...
PROSTATIC HYPERTROPHY | COMMUNITY MEDICINE | URINATION DISORDERS | URINARY SYMPTOMS | UROLOGY & NEPHROLOGY | PREVALENCE | QUALITY OF LIFE | HYPERPLASIA | Severity of Illness Index | Prostatic Hyperplasia - psychology | Humans | Middle Aged | Male | Patient Satisfaction | Prostatic Hyperplasia - complications | Prostatic Hyperplasia - surgery | Urination Disorders - etiology | Aged, 80 and over | Quality of Life | Surveys and Questionnaires | Aged | France
PROSTATIC HYPERTROPHY | COMMUNITY MEDICINE | URINATION DISORDERS | URINARY SYMPTOMS | UROLOGY & NEPHROLOGY | PREVALENCE | QUALITY OF LIFE | HYPERPLASIA | Severity of Illness Index | Prostatic Hyperplasia - psychology | Humans | Middle Aged | Male | Patient Satisfaction | Prostatic Hyperplasia - complications | Prostatic Hyperplasia - surgery | Urination Disorders - etiology | Aged, 80 and over | Quality of Life | Surveys and Questionnaires | Aged | France
Journal Article
Pediatrics, ISSN 0031-4005, 06/2014, Volume 133, Issue 6, pp. e1792 - e1797
Plexiform neurofibromas (PNs) are common and potentially debilitating complications of neurofibromatosis 1 (NF1). These benign nerve-sheath tumors are...
Neurofibromatosis type 1 | Plexiform neurofibromas | Sirolimus | Pain management | Therapeutics | MAMMALIAN TARGET | therapeutics | TYPE-1 NEUROFIBROMATOSIS | plexiform neurofibromas | pain management | RAPAMYCIN PATHWAY | RAS PROTEINS | MTOR | INFLAMMATION | sirolimus | IN-VIVO | neurofibromatosis type 1 | PEDIATRICS | LOCAL TRANSLATION | SCHWANN-CELLS | NERVE SHEATH TUMORS | Chronic Pain - diagnosis | Sirolimus - therapeutic use | Chronic Pain - drug therapy | Drug Administration Schedule | Follow-Up Studies | Abdominal Neoplasms - drug therapy | Humans | Cooperative Behavior | Male | Neurofibromatosis 1 - diagnosis | Pain Measurement - drug effects | Abdominal Neoplasms - diagnosis | Neurofibroma, Plexiform - drug therapy | Neurofibroma, Plexiform - diagnosis | Dose-Response Relationship, Drug | Interdisciplinary Communication | Neurofibromatosis 1 - drug therapy | Adolescent | Female | Child | Sirolimus - adverse effects | Complications and side effects | Care and treatment | Pain | Analysis | Neurofibroma | Epidemiology | Medical treatment | Morbidity | Tumors
Neurofibromatosis type 1 | Plexiform neurofibromas | Sirolimus | Pain management | Therapeutics | MAMMALIAN TARGET | therapeutics | TYPE-1 NEUROFIBROMATOSIS | plexiform neurofibromas | pain management | RAPAMYCIN PATHWAY | RAS PROTEINS | MTOR | INFLAMMATION | sirolimus | IN-VIVO | neurofibromatosis type 1 | PEDIATRICS | LOCAL TRANSLATION | SCHWANN-CELLS | NERVE SHEATH TUMORS | Chronic Pain - diagnosis | Sirolimus - therapeutic use | Chronic Pain - drug therapy | Drug Administration Schedule | Follow-Up Studies | Abdominal Neoplasms - drug therapy | Humans | Cooperative Behavior | Male | Neurofibromatosis 1 - diagnosis | Pain Measurement - drug effects | Abdominal Neoplasms - diagnosis | Neurofibroma, Plexiform - drug therapy | Neurofibroma, Plexiform - diagnosis | Dose-Response Relationship, Drug | Interdisciplinary Communication | Neurofibromatosis 1 - drug therapy | Adolescent | Female | Child | Sirolimus - adverse effects | Complications and side effects | Care and treatment | Pain | Analysis | Neurofibroma | Epidemiology | Medical treatment | Morbidity | Tumors
Journal Article
Journal of Urology, ISSN 0022-5347, 1994, Volume 151, Issue 5, pp. 1266 - 1270
The prevalence of urinary symptoms associated with benign prostatic hyperplasia was studied in a community-based, nationwide, representative sample of 2,011...
epidemiology | community medicine | urination disorders | prostatic hypertrophy | France - epidemiology | Prevalence | Prostatic Hyperplasia - diagnosis | Humans | Middle Aged | Aged, 80 and over | Male | Aged | Prostatic Hyperplasia - epidemiology | Prostatic Hyperplasia - surgery
epidemiology | community medicine | urination disorders | prostatic hypertrophy | France - epidemiology | Prevalence | Prostatic Hyperplasia - diagnosis | Humans | Middle Aged | Aged, 80 and over | Male | Aged | Prostatic Hyperplasia - epidemiology | Prostatic Hyperplasia - surgery
Journal Article
BJU International, ISSN 1464-4096, 12/2004, Volume 94, Issue 3, pp. 3 - 4
Journal Article
GASTROENTEROLOGY, ISSN 0016-5085, 11/2004, Volume 127, Issue 5, pp. 1386 - 1390
Background & Aims: Most human and animal cholestatic disorders are associated with changes in hepatocyte cytoskeleton and tight junctions (TJs). These changes...
LOCALIZATION | BARRIER | GASTROENTEROLOGY & HEPATOLOGY
LOCALIZATION | BARRIER | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Clinical Epidemiology, ISSN 0895-4356, 1996, Volume 49, Issue 10, pp. 1171 - 1176
As part of a large, nationwide community-based study in France on health and urinary condition, involving 2011 men aged between 50 and 80 years, information...
survey | sexual life | Urinary symptoms | France | Sexual life | Survey | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | QUALITY | SYMPTOMS | PREVALENCE | HYPERPLASIA | urinary symptoms | BENIGN PROSTATIC HYPERTROPHY | TRANSURETHRAL RESECTION | Sexual Behavior | Ejaculation | Humans | Middle Aged | Urination Disorders - psychology | Aged, 80 and over | Male | Aged | Personal Satisfaction
survey | sexual life | Urinary symptoms | France | Sexual life | Survey | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | QUALITY | SYMPTOMS | PREVALENCE | HYPERPLASIA | urinary symptoms | BENIGN PROSTATIC HYPERTROPHY | TRANSURETHRAL RESECTION | Sexual Behavior | Ejaculation | Humans | Middle Aged | Urination Disorders - psychology | Aged, 80 and over | Male | Aged | Personal Satisfaction
Journal Article
Oncogene, ISSN 0950-9232, 03/2006, Volume 25, Issue 14, pp. 2113 - 2118
A subset of upper urinary tract urothelial cell carcinomas (UUC), arising sporadically or as a manifestation of hereditary non-polyposis colorectal cancer,...
Upper urinary tract | Urothelial cell carcinoma | Microsatellite instability | Hereditary non-polyposis colorectal cancer | MSI phenotype | Renal pelvis | microsatellite instability | hereditary non-polyposis colorectal cancer | NONPOLYPOSIS COLORECTAL-CANCER | REPAIR-DEFICIENT CANCERS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MRE11 EXPRESSION | MISMATCH-REPAIR | HMLH1 | upper urinary tract | TUMORS | LINES | CELL BIOLOGY | TARGET GENES | ONCOLOGY | GENETICS & HEREDITY | urothelial cell carcinoma | renal pelvis | FRAMESHIFT MUTATIONS | MONONUCLEOTIDE REPEATS | Immunohistochemistry | Humans | Middle Aged | Male | Gene Expression Profiling | Urothelium - pathology | Microsatellite Repeats - genetics | Urinary Bladder Neoplasms - genetics | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Mutation
Upper urinary tract | Urothelial cell carcinoma | Microsatellite instability | Hereditary non-polyposis colorectal cancer | MSI phenotype | Renal pelvis | microsatellite instability | hereditary non-polyposis colorectal cancer | NONPOLYPOSIS COLORECTAL-CANCER | REPAIR-DEFICIENT CANCERS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MRE11 EXPRESSION | MISMATCH-REPAIR | HMLH1 | upper urinary tract | TUMORS | LINES | CELL BIOLOGY | TARGET GENES | ONCOLOGY | GENETICS & HEREDITY | urothelial cell carcinoma | renal pelvis | FRAMESHIFT MUTATIONS | MONONUCLEOTIDE REPEATS | Immunohistochemistry | Humans | Middle Aged | Male | Gene Expression Profiling | Urothelium - pathology | Microsatellite Repeats - genetics | Urinary Bladder Neoplasms - genetics | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Mutation
Journal Article
European Urology, ISSN 0302-2838, 2005, Volume 48, Issue 2, pp. 269 - 276
Sexual function is one of the aspects in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) that has...
Tamsulosin | Permixon | Finasteride | BPH | LUTS | Sexual function | MULTICENTER | sexual function | EFFICACY | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Enzyme Inhibitors - adverse effects | Humans | Adrenergic alpha-Antagonists - therapeutic use | Serenoa - adverse effects | Urodynamics - drug effects | Male | Treatment Outcome | Enzyme Inhibitors - therapeutic use | Randomized Controlled Trials as Topic | Finasteride - adverse effects | Adrenergic alpha-Antagonists - adverse effects | Sulfonamides - therapeutic use | Androgen Antagonists - therapeutic use | Sulfonamides - adverse effects | Surveys and Questionnaires | Finasteride - therapeutic use | Sexual Behavior - drug effects | Androgen Antagonists - adverse effects | Plant Extracts - therapeutic use | Prostatic Hyperplasia - drug therapy | Plant Extracts - adverse effects | Tamsulosin hydrochloride | Care and treatment | Analysis | Antiandrogens | Sexual disorders | Prostate | Hypertrophy
Tamsulosin | Permixon | Finasteride | BPH | LUTS | Sexual function | MULTICENTER | sexual function | EFFICACY | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Enzyme Inhibitors - adverse effects | Humans | Adrenergic alpha-Antagonists - therapeutic use | Serenoa - adverse effects | Urodynamics - drug effects | Male | Treatment Outcome | Enzyme Inhibitors - therapeutic use | Randomized Controlled Trials as Topic | Finasteride - adverse effects | Adrenergic alpha-Antagonists - adverse effects | Sulfonamides - therapeutic use | Androgen Antagonists - therapeutic use | Sulfonamides - adverse effects | Surveys and Questionnaires | Finasteride - therapeutic use | Sexual Behavior - drug effects | Androgen Antagonists - adverse effects | Plant Extracts - therapeutic use | Prostatic Hyperplasia - drug therapy | Plant Extracts - adverse effects | Tamsulosin hydrochloride | Care and treatment | Analysis | Antiandrogens | Sexual disorders | Prostate | Hypertrophy
Journal Article
European Neuropsychopharmacology, ISSN 0924-977X, 2019, Volume 29, pp. S38 - S39
Journal Article
The Journal of Urology, ISSN 0022-5347, 1996, Volume 155, Issue 4, pp. 1340 - 1343
Approximately 50 percent of all malignant prostatic tumors contain neuroendocrine cells, which cannot be attributed to small cell prostatic carcinoma or...
phosphopyruvate hydratase | chromogranins | neuroendocrine tumors | prostatic neoplasms | SYSTEM | CELLS | CANCER | PEPTIDE | SOMATOSTATIN | GROWTH | UROLOGY & NEPHROLOGY | SEROTONIN | DIFFERENTIATION | Immunoassay | Calcitonin - blood | Chromogranin A | Prognosis | Humans | Middle Aged | Male | Survival Rate | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Substance P - blood | Biomarkers, Tumor - blood | Neuropeptides - blood | Neurotensin - blood | Chromogranins - blood | Somatostatin - blood | Phosphopyruvate Hydratase - blood | Aged, 80 and over | Prostatic Neoplasms - blood | Prostatic Hyperplasia - blood | Aged | Acid Phosphatase - blood | Bombesin - blood | Care and treatment | Carcinoma | Cancer
phosphopyruvate hydratase | chromogranins | neuroendocrine tumors | prostatic neoplasms | SYSTEM | CELLS | CANCER | PEPTIDE | SOMATOSTATIN | GROWTH | UROLOGY & NEPHROLOGY | SEROTONIN | DIFFERENTIATION | Immunoassay | Calcitonin - blood | Chromogranin A | Prognosis | Humans | Middle Aged | Male | Survival Rate | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Substance P - blood | Biomarkers, Tumor - blood | Neuropeptides - blood | Neurotensin - blood | Chromogranins - blood | Somatostatin - blood | Phosphopyruvate Hydratase - blood | Aged, 80 and over | Prostatic Neoplasms - blood | Prostatic Hyperplasia - blood | Aged | Acid Phosphatase - blood | Bombesin - blood | Care and treatment | Carcinoma | Cancer
Journal Article
18.
Full Text
Management of prostate-specific antigen relapse in prostate cancer: A European concensus
International Journal of Clinical Practice, ISSN 1368-5031, 04/2004, Volume 58, Issue 4, pp. 382 - 390
Journal Article
European Urology, ISSN 0302-2838, 09/2006, Volume 50, Issue 3, pp. 555 - 562
Knowledge of the clinical profile of the population with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) is important for health care...
Benign prostatic hyperplasia | Lower urinary tract symptoms | TRIUMPH | International Prostate Symptom Score | FOLLOW-UP | PREVALENCE | URINARY-TRACT SYMPTOMS | MEN | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | SEXUAL DYSFUNCTION | BPH | lower urinary tract symptoms | ASSOCIATION | benign prostatic hyperplasia | France - epidemiology | Comorbidity | Humans | Middle Aged | Europe - epidemiology | Male | Patient Acceptance of Health Care - statistics & numerical data | Mass Screening - methods | Poland - epidemiology | Patient Selection | Prostatic Hyperplasia - complications | Prostatic Hyperplasia - epidemiology | Urologic Diseases - epidemiology | Spain - epidemiology | Italy - epidemiology | Aged | Referral and Consultation | Urologic Diseases - complications | United Kingdom - epidemiology | Medical colleges | Physicians (General practice) | Medical care, Cost of
Benign prostatic hyperplasia | Lower urinary tract symptoms | TRIUMPH | International Prostate Symptom Score | FOLLOW-UP | PREVALENCE | URINARY-TRACT SYMPTOMS | MEN | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | SEXUAL DYSFUNCTION | BPH | lower urinary tract symptoms | ASSOCIATION | benign prostatic hyperplasia | France - epidemiology | Comorbidity | Humans | Middle Aged | Europe - epidemiology | Male | Patient Acceptance of Health Care - statistics & numerical data | Mass Screening - methods | Poland - epidemiology | Patient Selection | Prostatic Hyperplasia - complications | Prostatic Hyperplasia - epidemiology | Urologic Diseases - epidemiology | Spain - epidemiology | Italy - epidemiology | Aged | Referral and Consultation | Urologic Diseases - complications | United Kingdom - epidemiology | Medical colleges | Physicians (General practice) | Medical care, Cost of
Journal Article
Journal of Endourology, ISSN 0892-7790, 02/2007, Volume 21, Issue 2, pp. 173 - 176
Purpose: To improve the quality of life of patients with palliative definitive percutaneous nephrostomy, we prospectively evaluated a subcutaneous ureteral...
UROLOGY & NEPHROLOGY | EXPERIENCE | Prosthesis Implantation | Prospective Studies | Urography | Humans | Nephrostomy, Percutaneous | Quality of Life | Female | Male | Palliative Care | Aged
UROLOGY & NEPHROLOGY | EXPERIENCE | Prosthesis Implantation | Prospective Studies | Urography | Humans | Nephrostomy, Percutaneous | Quality of Life | Female | Male | Palliative Care | Aged
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.